Free Access
Issue
Med Sci (Paris)
Volume 34, Number 6-7, Juin–Juillet 2018
Les Cahiers de Myologie
Page(s) 516 - 518
Section Le Magazine
DOI https://doi.org/10.1051/medsci/20183406007
Published online 31 July 2018
  1. Robert C, Mateus C. Anticorps anti-CTLA-4 : une avancée thérapeutique majeure dans le traitement du mélanome métastatique. Med Sci (Paris) 2011 ; 27 : 850–858. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  2. Champiat S, Soria JC. Nouvelles pratiques en immuno-oncologie : une révolution et un immense défit scientifique et médical. Med Sci (Paris) 2017 ; 33 : 563–564. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  3. Olive D, le Thi S, Xerri L, Hirsch I, Nunès JA. Rôle de CTLA-4 dans la co-signalisation négative du système immunitaire. Med Sci (Paris) 2011 ; 27 : 842–849. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  4. Ueda H, Howson JMM, Esposito L, et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003 ; 423 : 506–11. [CrossRef] [PubMed] [Google Scholar]
  5. Prokunina L, Castillejo-López C, Oberg F, et al. A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet 2002 ; 32 : 666–669. [Google Scholar]
  6. Kremer JM, Westhovens R, Leon M, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003 ; 349 : 1907–1915. [Google Scholar]
  7. Vincenti F, Rostaing L, Grinyo J, et al. Belatacept and long-term outcomes in kidney transplantation. N Engl J Med 2016 ; 374 : 333–343. [Google Scholar]
  8. Haratani K, Hayashi H, Chiba Y, et al. Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer. JAMA Oncol 2018 ; 4 : 374–378. [CrossRef] [PubMed] [Google Scholar]
  9. Weber JS, Hodi FS, Wolchok JD, et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol 2017 ; 35 : 785–792. [CrossRef] [PubMed] [Google Scholar]
  10. Danlos F-X, Voisin A-L, Dyevre V, et al. Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. Eur J Cancer 2018 ; 91 : 21–29. [CrossRef] [PubMed] [Google Scholar]
  11. Abdel-Wahab N, Shah M, Lopez-Olivo MA, Suarez-Almazor ME. Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: A systematic review. Ann Intern Med 2018; 168 : 121–130. [CrossRef] [PubMed] [Google Scholar]
  12. Johnson DB, Sullivan RJ, Ott PA, et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol 2016 ; 2 : 234–240. [CrossRef] [PubMed] [Google Scholar]
  13. Menzies AM, Johnson DB, Ramanujam S, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol 2017 ; 28 : 368–76. [CrossRef] [PubMed] [Google Scholar]
  14. Gutzmer R, Koop A, Meier F, et al. Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity. Eur J Cancer 2017 ; 75 : 24–32. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.